| P2093 | author name string | Deborah Hinnen | |
| P2860 | cites work | A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus | Q26765155 |
| | Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists | Q26823085 |
| | Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. | Q27687851 |
| | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 |
| | Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. | Q51599426 |
| | A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. | Q51653312 |
| | Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria | Q58448092 |
| | Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment | Q59942672 |
| | Reduced incretin effect in type 2 (non-insulin-dependent) diabetes | Q68865252 |
| | PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION | Q77059466 |
| | Pancreatic safety of incretin-based drugs--FDA and EMA assessment | Q28308049 |
| | American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015 | Q28384855 |
| | Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis | Q28546797 |
| | Biology of incretins: GLP-1 and GIP | Q29617302 |
| | Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies | Q30848457 |
| | Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database | Q34422144 |
| | Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q34540403 |
| | Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies | Q34996877 |
| | Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis | Q35537079 |
| | The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis | Q35677315 |
| | The potential role of glucagon-like peptide 1 in diabetes. | Q35768007 |
| | Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis | Q35769898 |
| | Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study | Q36248001 |
| | Biologic actions and therapeutic potential of the proglucagon-derived peptides | Q36575421 |
| | Therapy in the early stage: incretins | Q36783865 |
| | Glucagon-like peptide-1 analogues: An overview | Q37015969 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | New injection recommendations for patients with diabetes | Q37798971 |
| | Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes | Q37900626 |
| | GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus | Q38040314 |
| | Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies | Q38242089 |
| | Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes | Q38374021 |
| | Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. | Q38394585 |
| | The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions | Q38733474 |
| | Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. | Q39732229 |
| | The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. | Q40585257 |
| | CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. | Q41000321 |
| | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 |
| | Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations | Q43080178 |
| | Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials | Q43446368 |
| | Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study | Q43919658 |
| | Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes | Q44295713 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 202-210 | |
| P577 | publication date | 2017-08-01 | |
| P1433 | published in | Diabetes spectrum : a publication of the American Diabetes Association | Q27722982 |
| P1476 | title | Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes | |
| P478 | volume | 30 | |